WA-SPIE
11.1.2022 18:39:07 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics , today announced the recipients of its prestigious annual awards . Honoring transformative advancements in multiple areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005942/en/
SPIE Gold Medal: Michael Berns
In recognition of his work in bioengineering research and his distinguished career that brought together engineers, physicists, biologists, and physicians to collaborate on ground-breaking discoveries and innovations.
SPIE President's Award: Tuan Vo-Dinh
In recognition of his outstanding and extensive role in SPIE conference leadership, in disparate technical areas, and for his mentorship of early investigators as well as peers.
SPIE Directors' Award: Julie Bentley
In recognition of her outstanding service to the Society in extraordinary ways, including authorship, course instruction, conference program leadership, committee membership, and service on the Board of Directors.
SPIE Mozi Award: Thomas W. Ebbesen
In recognition of his phenomenal contributions to the field of nano-optics, especially the extraordinary optical transmission through sub-wavelength hole arrays.
SPIE Britton Chance Award in Biomedical Optics: Bruce Tromberg
In recognition of his high-impact translational research and overall leadership in the development of biophotonic technologies for diagnostics and therapeutics.
SPIE Biophotonics Technology Innovator Award: Bert Müller
In recognition of his distinguished contributions to 2D and 3D imaging for the challenges of the 21st century, including cardiovascular and neurodegenerative diseases, bioinspired dental repair, and incontinence treatment.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Masato Shibuya
In recognition of his significant contributions to the development of optical design through the invention of phase-shift masks for photolithography, and for laying the foundations of imaging theory based on plane-wave expansions.
SPIE Harrison H. Barrett Award in Medical Imaging: Maryellen Giger
In recognition of her pioneering work in the fields of digital image formation, computer-aided diagnosis, radiomics, and radiogenomics.
SPIE Harold E. Edgerton Award in High-Speed Optics: Mona Jarrahi
In recognition of her pioneering contributions to plasmonic time-domain spectroscopy and imaging systems as well as their scientific and industrial applications.
SPIE Dennis Gabor Award in Diffractive Optics: Gabriel Popescu
In recognition of his groundbreaking contributions to holography and quantitative phase imaging for biomedical applications.
SPIE George W. Goddard Award in Space and Airborne Optics: Michelle Stephens
In recognition of her technical innovation, mentoring, and exceptional leadership in pursuit of space-based, fundamental measurements of the Earth and Sun, while reducing technological barriers and promoting standards for the advancement of space and airborne optics.
SPIE G. G. Stokes Award in Optical Polarization: Alex Vitkin
In recognition of his extensive contributions to tissue polarimetry, including advanced methodology developments for sensitive and robust Stokes and Mueller measurements; polarimetric computational and analytical platforms; and biomedical applications including cardiology, regenerative medicine, glucometry, and breast-cancer margin assessment.
SPIE Chandra S. Vikram Award in Optical Metrology: Jürgen Czarske
In recognition of his important contributions to computational laser metrology with paradigm changes in fluid dynamics, inspection, aerospace, communication, and biomedicine.
SPIE Frits Zernike Award for Microlithography: Harry J. Levinson
In recognition of his outstanding achievements contributing to our fundamental understanding of advanced lithography process control, especially in the concepts of Image-Log-Slope, Mask defect printability, and thin-film optics optimization.
SPIE Diversity Outreach Award: Qaisar Abbas Naqvi
In recognition of his inspirational attitude and dedication to students, helping transform the lives of women and men from traditionally under-recognized segments of society by supporting their pursuit of higher education and research in optics and related fields.
SPIE Maria Goeppert-Mayer Award in Photonics: Shin-Tson Wu
In recognition of his seminal contributions to display and photonic device technologies that led to widespread applications.
SPIE Maiman Laser Award: Bill Krupke
In recognition of his scientific, technical and community leadership, innovation, and numerous seminal results in laser science and technology.
SPIE Early Career Achievement Award — Academic Focus: Bhavin Shastri
In recognition of his pioneering efforts in the field of neuromorphic photonics and his contributions to interdisciplinary research across nanophotonics, unconventional computing, and silicon photonics that pushed the frontiers of machine learning.
SPIE Early Career Achievement Award — Industry/Government Focus: Lionel Clermont
In recognition of his significant achievements in the field of stray light control, particularly his work on the development of the ultrafast time-of-flight imaging characterization method.
SPIE Maria J. Yzuel Educator Award: Rajpal Sirohi
In recognition of his many years of service in the field of optics through leadership, capacity building, and outreach.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Ge Wang
In recognition of his pioneering contributions in X-ray and optical molecular tomography, including their coupling for biomedical applications.
The complete listing of all SPIE awards and recipients is available here .
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom